LOGIN  |  REGISTER
Assertio

Waters Announces Seamless HPLC/UPLC Data Bridge for Light Scattering, Integrating Essential Instruments for Large Molecule Characterization

February 26, 2024 | Last Trade: US$357.77 13.06 3.79

News Summary:

  • Waters now enables seamless connectivity between its liquid chromatography (LC) systems and multi-angle light-scattering instruments (MALS) for improved ease-of-use, efficiency, and data confidence in characterizing large molecules.
  • HPLC CONNECT™ software accelerates precise characterization of complex molecules for the development of biologic drugs, including antibody drug conjugates, other complex protein conjugates, and gene therapies.
  • Unified interface enables single point of control and data collection, eliminating manual processes to help reduce human error and deliver high certainty in the data generated during acquisition and post-acquisition for analysis.

SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- Pittcon 2024 – Waters Corporation (NYSE:WAT) announced HPLC CONNECT software, an all-in-one software platform that enables full digital synchronization between Waters high- and ultra-performance liquid chromatography (HPLC/UPLC) systems and multi-angle light-scattering instruments (MALS) from its Wyatt Technology™ portfolio. The software delivers ease-of-use, greater efficiency, and higher confidence for scientists performing size exclusion chromatography and MALS (SEC-MALS) analyses for complex and critical biopharmaceutical innovations, including antibody drug conjugates, other complex protein conjugates, and gene therapies.

"Drug development scientists today are working with novel modalities that require advanced and comprehensive measurements for the development of new and potentially life-saving biologic drugs," said Fraser McLeod, Vice President, General Manager, QA/QC and Wyatt Technology, Waters Corporation. "The team delivered this product integration ahead of schedule to greatly simplify the characterization of complex molecules – a critical step in developing biologics. Waters HPLC CONNECT software removes a significant amount of labor, reduces risk of human error, and delivers unmatched confidence in the data generated during analysis."

HPLC CONNECT software supports select Waters™ LC systems including the ACQUITY™ Premier, Arc Premier, and Arc Systems. The software enables users to control and monitor HPLC modules including pumps, column ovens, UV detectors, and autosamplers from a single dashboard view.

Waters offers a full line of SEC columns optimized for separation of biomolecules by size, ideal for monoclonal antibodies, proteins, peptides, and other biologics.

Waters HPLC CONNECT software is now available globally.

Additional Resources

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 8,000 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.

Waters, HPLC CONNECT, Wyatt Technology, and ACQUITY are trademarks of Waters Technologies Corporation.

Contact:

Janice Foley
Senior Public Relations Manager
Waters Corporation
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1.617.823.5555

Waters HPLC CONNECT™ is an all-in-one software platform that enables full digital synchronization between Waters HPLC and UPLC systems and multi-angle light-scattering instruments (MALS) from its Wyatt Technology™ portfolio.

 

Recursion

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB